Eterna Therapeutics Stock Probability of Future Stock Price Finishing Over 0.25
| ERNA Stock | USD 0.25 0.02 7.41% |
Eterna |
Eterna Therapeutics Target Price Odds to finish over 0.25
The tendency of Eterna Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.25 | 90 days | 0.25 | over 95.32 |
Based on a normal probability distribution, the odds of Eterna Therapeutics to move above the current price in 90 days from now is over 95.32 (This Eterna Therapeutics probability density function shows the probability of Eterna Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Eterna Therapeutics has a beta of 0.42 suggesting as returns on the market go up, Eterna Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Eterna Therapeutics will be expected to be much smaller as well. Additionally Eterna Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Eterna Therapeutics Price Density |
| Price |
Predictive Modules for Eterna Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Eterna Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Eterna Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Eterna Therapeutics is not an exception. The market had few large corrections towards the Eterna Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Eterna Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Eterna Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -2.16 | |
β | Beta against Dow Jones | 0.42 | |
σ | Overall volatility | 0.34 | |
Ir | Information ratio | -0.29 |
Eterna Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Eterna Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Eterna Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Eterna Therapeutics generated a negative expected return over the last 90 days | |
| Eterna Therapeutics has high historical volatility and very poor performance | |
| Eterna Therapeutics has some characteristics of a very speculative penny stock | |
| Eterna Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 68 K. Net Loss for the year was (21.67 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Eterna Therapeutics currently holds about 19.41 M in cash with (20.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.6, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Eterna Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from newswire.com: BTX Precision Announces Acquisition of A-1 Jays Machining, A-1 Jays Sheet Metal, Inotech Laser, Bay Area Grinding and Silicon Valley Precision Cleaning |
Eterna Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Eterna Stock often depends not only on the future outlook of the current and potential Eterna Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Eterna Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 5.3 M | |
| Cash And Short Term Investments | 7.6 M |
Eterna Therapeutics Technical Analysis
Eterna Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Eterna Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Eterna Therapeutics. In general, you should focus on analyzing Eterna Stock price patterns and their correlations with different microeconomic environments and drivers.
Eterna Therapeutics Predictive Forecast Models
Eterna Therapeutics' time-series forecasting models is one of many Eterna Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Eterna Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Eterna Therapeutics
Checking the ongoing alerts about Eterna Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Eterna Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Eterna Therapeutics generated a negative expected return over the last 90 days | |
| Eterna Therapeutics has high historical volatility and very poor performance | |
| Eterna Therapeutics has some characteristics of a very speculative penny stock | |
| Eterna Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 68 K. Net Loss for the year was (21.67 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Eterna Therapeutics currently holds about 19.41 M in cash with (20.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.6, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Eterna Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from newswire.com: BTX Precision Announces Acquisition of A-1 Jays Machining, A-1 Jays Sheet Metal, Inotech Laser, Bay Area Grinding and Silicon Valley Precision Cleaning |
Check out Eterna Therapeutics Backtesting, Eterna Therapeutics Valuation, Eterna Therapeutics Correlation, Eterna Therapeutics Hype Analysis, Eterna Therapeutics Volatility, Eterna Therapeutics History as well as Eterna Therapeutics Performance. For information on how to trade Eterna Stock refer to our How to Trade Eterna Stock guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eterna Therapeutics. If investors know Eterna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eterna Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.31) | Revenue Per Share 0.03 | Return On Assets (0.29) | Return On Equity (11.54) |
The market value of Eterna Therapeutics is measured differently than its book value, which is the value of Eterna that is recorded on the company's balance sheet. Investors also form their own opinion of Eterna Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Eterna Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eterna Therapeutics' market value can be influenced by many factors that don't directly affect Eterna Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eterna Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eterna Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eterna Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.